PD-1 and VEGF-A — Drug Target

All drugs that target PD-1 and VEGF-A — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

PD-1 inhibitor and anti-VEGF monoclonal antibody

Phase 2 pipeline (1)

• Bevacizumab Biosimilar IBI305 plus sintilimab · Ze-yang Ding, MD · PD-1 inhibitor and anti-VEGF monoclonal antibody · Oncology
  Bevacizumab Biosimilar IBI305 is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while sintilimab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction.